Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 21%
Buy 14%
Hold 57%
Sell 7%
Strong Sell 0%

Bulls say

Pfizer is a global leader in the pharmaceutical industry with strong international sales and a diverse portfolio of top-selling prescription drugs and vaccines. Although the COVID-19 pandemic has affected its sales in the short term, the company is well-positioned for long-term growth with a strong pipeline and expanding into new areas such as muscle-invasive bladder cancer. The upcoming earnings call will provide insight into the company's progress and future plans, and we maintain a positive outlook on Pfizer's stock.

Bears say

Pfizer is facing challenges with patent expirations, a potential decline in sales from COVID-19 vaccines, and the need for positive pipeline data to improve investor sentiment. The company's 2Q 2026 results showed both positive developments, such as higher than expected Eliquis sales, and negative developments, such as lower COVID sales and reduced guidance. However, with a low 9.3x P/E ratio and a 6.6% dividend yield, the stock is still trading at a discount to its peers.

Pfizer (PFE) has been analyzed by 14 analysts, with a consensus rating of Hold. 21% of analysts recommend a Strong Buy, 14% recommend Buy, 57% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 14 analysts, Pfizer (PFE) has a Hold consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.